LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines.

    Pellar, Russell Edward / Pope, Janet Elizabeth

    Seminars in arthritis and rheumatism

    2017  Volume 46, Issue 6, Page(s) 767–774

    Abstract: Objectives: Systemic sclerosis (SSc) is a rare heterogeneous connective tissue disease. Recommendations addressing the major issues in the management of SSc including screening and treatment of organ complications are needed.: Methods: The updated ... ...

    Abstract Objectives: Systemic sclerosis (SSc) is a rare heterogeneous connective tissue disease. Recommendations addressing the major issues in the management of SSc including screening and treatment of organ complications are needed.
    Methods: The updated European League Against Rheumatism/European Scleroderma Trial and Research (EULAR/EUSTAR) and the British Society of Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) guidelines were compared and contrasted.
    Results: The updated EULAR/EUSTAR guidelines focus specifically on the management of SSc features and include data on newer therapeutic modalities and mention a research agenda. These recommendations are pharmacologic, with few guidelines regarding investigations and non-pharmacologic management. Recommendations from BSR/BHPR are similar to the organ manifestations mentioned in the EULAR/EUSTAR recommendations, and expand on several domains of treatment, including general measures, non-pharmacologic treatment, cardiac involvement, calcinosis, and musculoskeletal features. The guidelines usually agree with one another. Limitations include the lack of guidance for combination or second-line therapy, algorithmic suggestions, the absence of evidence-based recommendations regarding the treatment of specific complications (i.e., gastric antral ectasia and erectile dysfunction). Consensus for when to treat interstitial lung disease in SSc is lacking. There are differences between Europe and North American experts due to access and indications for certain therapies.
    Conclusions: Care gaps in SSc have been demonstrated so the EULAR/EUSTAR and BSR/BHP guidelines can promote best practices. Certain complications warrant active investigation to further improve outcomes in SSc and future updates of these recommendations. Care gaps in SSc have been demonstrated so the EULAR/EUSTAR and BSR/BHP guidelines can promote best practices. Certain complications warrant active investigation to further improve outcomes in SSc.
    Language English
    Publishing date 2017-06
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 120247-9
    ISSN 1532-866X ; 0049-0172
    ISSN (online) 1532-866X
    ISSN 0049-0172
    DOI 10.1016/j.semarthrit.2016.12.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Raynaud's phenomenon (primary).

    Pope, Janet Elizabeth

    BMJ clinical evidence

    2011  Volume 2011

    Abstract: Introduction: Raynaud's phenomenon is an episodic vasospasm of the peripheral arteries, causing pallor, followed by cyanosis and redness with pain, and sometimes paraesthesia. On rare occasions it can lead to ulceration of the fingers and toes (and in ... ...

    Abstract Introduction: Raynaud's phenomenon is an episodic vasospasm of the peripheral arteries, causing pallor, followed by cyanosis and redness with pain, and sometimes paraesthesia. On rare occasions it can lead to ulceration of the fingers and toes (and in some cases of the ears or nose). This review focuses on primary (idiopathic) Raynaud's phenomenon, occurring in the absence of an underlying disease. The prevalence of primary Raynaud's phenomenon varies by sex, country, and exposure to workplace vibration.
    Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments for primary Raynaud's phenomenon? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
    Results: We found 16 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
    Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: amlodipine, diltiazem, exercise, inositol nicotinate, keeping warm, moxisylyte (thymoxamine), naftidrofuryl oxalate, nicardipine, nifedipine, prazosin, and smoking cessation.
    MeSH term(s) Administration, Oral ; Humans ; Nifedipine/therapeutic use ; Prevalence ; Raynaud Disease/drug therapy ; Ulcer ; Vibration
    Chemical Substances Nifedipine (I9ZF7L6G2L)
    Language English
    Publishing date 2011-03-14
    Publishing country England
    Document type Journal Article ; Review ; Systematic Review
    ZDB-ID 2393858-4
    ISSN 1752-8526 ; 1757-0816 ; 1475-9225
    ISSN (online) 1752-8526
    ISSN 1757-0816 ; 1475-9225
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Raynaud's phenomenon (primary).

    Pope, Janet Elizabeth

    BMJ clinical evidence

    2008  Volume 2008

    Abstract: Introduction: Raynaud's phenomenon is an episodic vasospasm of the peripheral arteries, causing pallor followed by cyanosis and redness with pain and sometimes paraesthesia. On rare occasions it can lead to ulceration of the fingers and toes (and in ... ...

    Abstract Introduction: Raynaud's phenomenon is an episodic vasospasm of the peripheral arteries, causing pallor followed by cyanosis and redness with pain and sometimes paraesthesia. On rare occasions it can lead to ulceration of the fingers and toes (and in some cases of the ears or nose). This review focuses on primary (idiopathic) Raynaud's phenomenon occurring in the absence of an underlying disease. The prevalence of primary Raynaud's phenomenon varies by sex, country, and exposure to workplace vibration.
    Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments for primary Raynaud's phenomenon? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2008 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
    Results: We found 15 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
    Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: amlodipine, diltiazem, exercise, inositol nicotinate, keeping warm, moxisylyte (thymoxamine), naftidrofuryl oxalate, nicardipine, nifedipine, prazosin, and smoking cessation.
    MeSH term(s) Administration, Oral ; Humans ; Nifedipine/therapeutic use ; Prevalence ; Raynaud Disease/drug therapy ; Ulcer ; Vibration
    Chemical Substances Nifedipine (I9ZF7L6G2L)
    Language English
    Publishing date 2008-12-16
    Publishing country England
    Document type Journal Article ; Review ; Systematic Review
    ZDB-ID 2393858-4
    ISSN 1752-8526 ; 1757-0816 ; 1475-9225
    ISSN (online) 1752-8526
    ISSN 1757-0816 ; 1475-9225
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Patient-Reported Outcome Measures in Systemic Sclerosis (Scleroderma).

    Pellar, Russell E / Tingey, Theresa M / Pope, Janet Elizabeth

    Rheumatic diseases clinics of North America

    2016  Volume 42, Issue 2, Page(s) 301–316

    Abstract: Scleroderma (systemic sclerosis) is a rare autoimmune connective tissue disease that can damage multiple organs and reduce quality of life. Patient-reported outcome measures capture the patient's perspective. Some measures are specific to systemic ... ...

    Abstract Scleroderma (systemic sclerosis) is a rare autoimmune connective tissue disease that can damage multiple organs and reduce quality of life. Patient-reported outcome measures capture the patient's perspective. Some measures are specific to systemic sclerosis and others are general. Patient-reported outcomes in systemic sclerosis are important to aid in understanding the impact of systemic sclerosis on patients.
    MeSH term(s) Activities of Daily Living ; Humans ; Mental Health ; Patient Reported Outcome Measures ; Quality of Life ; Scleroderma, Systemic/physiopathology ; Social Participation ; Surveys and Questionnaires
    Language English
    Publishing date 2016-05
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 92118-x
    ISSN 1558-3163 ; 0889-857X
    ISSN (online) 1558-3163
    ISSN 0889-857X
    DOI 10.1016/j.rdc.2016.01.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top